Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...

Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

The transaction is led by MCR Investors and its Chairman and CEO, Tyler Morse, with financing from Apollo and Goldman Sachs ...